Literature DB >> 28255886

Selection of Aptamers Against Whole Living Cells: From Cell-SELEX to Identification of Biomarkers.

Nam Nguyen Quang1, Anna Miodek1, Agnes Cibiel1, Frédéric Ducongé2.   

Abstract

Aptamer selection protocols, named cell-SELEX, have been developed to target trans-membrane proteins using whole living cells as target. This technique presents several advantages. (1) It does not necessitate the use of purified proteins. (2) Aptamers are selected against membrane proteins in their native conformation. (3) Cell-SELEX can be performed to identify aptamers against biomarkers differentially expressed between different cell lines without prior knowledge of the targets. (4) Aptamers identified by cell-SELEX can be further used to purify their targets and to identify new biomarkers. Here, we provide a protocol of cell-SELEX including the preparation of an oligonucleotide library, next-generation sequencing and radioactive binding assays. Furthermore, we also provide a protocol to purify and identify the target of these aptamers. These protocols could be useful for the discovery of lead therapeutic compounds and diagnostic cell-surface biomarkers.

Entities:  

Keywords:  Aptamer; Biomarkers; Cell-SELEX; Oligonucleotides

Mesh:

Substances:

Year:  2017        PMID: 28255886     DOI: 10.1007/978-1-4939-6857-2_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Time-lapse imaging of molecular evolution by high-throughput sequencing.

Authors:  Nam Nguyen Quang; Clément Bouvier; Adrien Henriques; Benoit Lelandais; Frédéric Ducongé
Journal:  Nucleic Acids Res       Date:  2018-09-06       Impact factor: 16.971

2.  Optimization of RNA Aptamer SELEX Methods: Improved Aptamer Transcript 3'-End Homogeneity, PAGE Purification Yield, and Target-Bound Aptamer RNA Recovery.

Authors:  Chandan Narayan; Suresh Veeramani; William H Thiel
Journal:  Nucleic Acid Ther       Date:  2021-11-10       Impact factor: 5.486

Review 3.  Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers.

Authors:  Marie-Cécile Mercier; Monique Dontenwill; Laurence Choulier
Journal:  Cancers (Basel)       Date:  2017-06-21       Impact factor: 6.639

Review 4.  Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.

Authors:  Zhenjian Zhuo; Yuanyuan Yu; Maolin Wang; Jie Li; Zongkang Zhang; Jin Liu; Xiaohao Wu; Aiping Lu; Ge Zhang; Baoting Zhang
Journal:  Int J Mol Sci       Date:  2017-10-14       Impact factor: 5.923

Review 5.  Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology.

Authors:  Chan Chen; Shan Zhou; Yongqiang Cai; Faqing Tang
Journal:  NPJ Precis Oncol       Date:  2017-11-14

Review 6.  Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.

Authors:  Kamal Rahimizadeh; Hadi AlShamaileh; Milena Fratini; Madhuri Chakravarthy; Michelle Stephen; Sarah Shigdar; Rakesh N Veedu
Journal:  Molecules       Date:  2017-11-27       Impact factor: 4.411

Review 7.  Aptamers: novelty tools for cancer biology.

Authors:  Ricardo L Pereira; Isis C Nascimento; Ana P Santos; Isabella E Y Ogusuku; Claudiana Lameu; Günter Mayer; Henning Ulrich
Journal:  Oncotarget       Date:  2018-06-01

8.  Identification of Major Capsid Protein as a Potential Biomarker of Grouper Iridovirus-Infected Cells Using Aptamers Selected by SELEX.

Authors:  Qing Yu; Mingzhu Liu; Shina Wei; Hehe Xiao; Siting Wu; Ke Ke; Xiaohong Huang; Qiwei Qin; Pengfei Li
Journal:  Front Microbiol       Date:  2019-11-28       Impact factor: 5.640

Review 9.  Implementation of High-Throughput Sequencing (HTS) in Aptamer Selection Technology.

Authors:  Natalia Komarova; Daria Barkova; Alexander Kuznetsov
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

Review 10.  Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.

Authors:  Domenica Musumeci; Chiara Platella; Claudia Riccardi; Federica Moccia; Daniela Montesarchio
Journal:  Cancers (Basel)       Date:  2017-12-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.